Ageing and the border between health and Disease

European Respiratory Journal

Volumn 44, Issue 5, 2014, Pages 1332-1352

  MacNee, William ^a   Rabinovich, Roberto A ^a   Choudhury, Gourab ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA POLYMERASE; FREE RADICAL; HISTONE DEACETYLASE; IMMUNOSUPPRESSIVE AGENT; MELATONIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; RESVERATROL; SIRTUIN; SULFORAPHANE; THEOPHYLLINE;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIVISION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DNA DEGRADATION; ENVIRONMENTAL FACTOR; EXTRAPULMONARY TUBERCULOSIS; HEALTH CARE; HOMEOSTASIS; HUMAN; INCIDENCE; INFLAMMATION; LONGEVITY; LOW DRUG DOSE; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MUSCLE STRENGTH; OSTEOPOROSIS; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; RISK FACTOR; SENESCENCE; SKELETAL MUSCLE; STEM CELL TRANSPLANTATION; TELOMERE; WEIGHT REDUCTION; ANIMAL; GENETIC EPIGENESIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; VASCULAR DISEASE;

AGING; ANIMALS; CHRONIC DISEASE; COMORBIDITY; EPIGENESIS, GENETIC; HUMANS; INFLAMMATION; MUSCLE, SKELETAL; OXIDATIVE STRESS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; VASCULAR DISEASES;

EID: 84920603238     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00134014     Document Type: Article

References (269)

1. Kirkwood TB. Understanding the odd science of aging. Cell 2005; 120: 437-447.
2. World Health Organization. Ageing and Life Course. Care and independence in older age. www.who.int/ageing/en Date last accessed: August 2014.
3. Dillin A, Gottschling DE, Nystrom T. The good and the bad of being connected: The integrons of aging. Curr Opin Cell Biol 2014; 26: 107-112.
4. De Grey ADNJ. Life span extension research and public debate: societal considerations. Studies Ethics Law Technol 2007; 1.
5. Harris RE, ed. Epidemiology of Chronic Diease Global Perspectives. Massachusetts, Jones and Bartlett Learning, 2013.
6. Spence AP, ed. Biology of Human Aging. 2nd Edn. Englewood Cliffs, Prentice Hall, 1995.
7. Hayflick L. Entropy explains aging, genetic determinism explains longevity, and undefined terminology explains misunderstanding both. PLoS Genet 2007; 3: e220.
8. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10: Suppl., S125-S130.
9. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans 2009; 37: 819-823.
10. Dodds C. Physiology of ageing. Anaesth Intensive Care Med 2006; 7: 456-458.
11. Knight J, Nigam Y. Exploring the anatomy and physiology of ageing. Part 1: The cardiovascular system. Nurs Times 2008; 104: 26-27.
12. Martin P, Poon LW, Hagberg B. Behavioral factors of longevity. J Aging Res 2011; 2011: 197590.
13. Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153: 1194-1217.
14. Tuder RM, Yoshida T, Fijalkowka I, et al. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc Am Thorac Soc 2006; 3: 673-679.
15. Gems D, Partridge L. Genetics of longevity in model organisms: debates and paradigm shifts. Annu Rev Physiol 2013; 75: 621-644.
16. Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature 2008; 454: 1065-1071.
17. Campisi J, Kim SH, Lim CS, et al. Cellular senescence, cancer and aging: The telomere connection. Exp Gerontol 2001; 36: 1619-1637.
18. Mereschcowski K. Theorie der zwei Plasmaarten als Grundlage der Symbiogenesis, einer neuen Lehre von der Entstehung der Organismen [The theory of two plasmas as the basis of symbiogenesis, a New Study or the Origins of Organisms]. Biol Centralbl 1910; 30: 353-367.
19. Sagan L. On the origin of mitosing cells. J Theor Biol 1967; 14: 255-274.
20. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495.
21. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002; 80: 780-787.
22. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298-300.
23. Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest 2013; 123: 951-957.
24. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 2006; 1067: 10-21.
25. Speakman JR, Selman C. The free-radical damage theory: accumulating evidence against the simple link of oxidative stress to ageing and life span. Bioessays 2011; 33: 255-259.
26. Liochev SI. Reflections on the theories of aging, of oxidative stress, and of science in general. Is it time to abandon the free radical (oxidative stress) theory of aging? Antioxid Redox Signal 2014 [In press DOI:10.1089/ars.2014.5928].
27. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012; 48: 158-167.
28. Hekimi S, Lapointe J, Wen Y. Taking a "good" look at free radicals in the aging process. Trends Cell Biol 2011; 21: 569-576.
29. Barja G. The mitochondrial free radical theory of aging. Prog Mol Biol Transl Sci 2014; 127: 1-27.
30. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242.
31. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004; 39: 687-699.
32. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
33. Saretzki G, Von Zglinicki T. Replicative aging, telomeres and oxidative stress. Ann N Y Acad Sci 2002; 959: 24-29.
34. Chan SR, Blackburn EH. Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 2004; 359: 109-121.
35. Boonekamp JJ, Simons MJ, Hemerik L, et al. Telomere length behaves as biomarker of somatic redundancy rather than biological age. Aging Cell 2013; 12: 330-332.
36. Kuilman T, Michaloglou C, Mooi WJ, et al. The essence of senescence. Genes Dev 2010; 24: 2463-2479.
37. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
38. Lombard DB, Chua KF, Mostoslavsky R, et al. DNA repair, genome stability, and aging. Cell 2005; 120: 497-512.
39. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130: 223-233.
40. Campisi J. Senescent cells, tumour suppression, organismal aging: good citizens, bad neighbours. Cell 2005; 120: 513-522.
41. Shelton DN, Chang E, Whittier PS, et al. Microarray analysis of replicative senescence. Curr Biol 1999; 9: 939-945.
42. Amsellem V, Gary-Bobo G, Marcos E, et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Med 2011; 184: 1358-1366.
43. Bitterman KJ, Anderson RM, Cohen HY, et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002; 277: 45099-45107.
44. Beauharnois JM, Bolivar BE, Welch JT. Sirtuin 6: a review of biological effects and potential therapeutic properties. Mol Biosyst 2013; 9: 1789-1806.
45. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007; 67: 3145-3152.
46. Espejel S, Franco S, Sgura A, et al. Functional interaction between DNA-PKcs and telomerase in telomere length maintenance. EMBO J 2002; 21: 6275-6287.
47. Powers ET, Morimoto RI, Dillin A, et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-991.
48. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011; 475: 324-332.
49. Calderwood SK, Murshid A, Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging - A mini-review. Gerontology 2009; 55: 550-558.
50. Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. Cell 2011; 146: 682-695.
51. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-254.
52. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001; 8: 131-136.
53. De Martinis M, Francheschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005; 579: 2035-2039.
54. Cevenini E, Monti D, Franceschi C. Inflamm-ageing. Curr Opin Clin Nutr Metab Care 2013; 16: 14-20.
55. Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY) 2012; 4: 166-175.
56. Fontana L, Partridge L, Longo VD. Extending healthy life span - from yeast to humans. Science 2010; 328: 321-326.
57. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
58. Akgun KA, Crothers K, Pisani M. Epidemiology and management of common pulmonary disease in older persons. J Gerontol A Biol Sci Med Sci 2012; 67: 276-291.
59. Vaz Fragoso CA, Gill TM. Respiratory impairment and the aging lung: a novel paradigm for assessing pulmonary function. J Gerontol A Biol Sci Med Sci 2012; 67: 264-275.
60. Chan ED, Welsh CH. Geriatric respiratory medicine. Chest 1998; 114: 1704-1733.
61. Janssens JP. Aging of the respiratory system: impact on pulmonary function tests and adaptation to exertion. Clin Chest Med 2005; 26: 469-484.
62. Tolep K, Kelsen SG. Effect of aging on respiratory skeletal muscles. Clin Chest Med 1993; 14: 363-378.
63. Polkey MI, Harris ML, Hughes PD, et al. The contractile properties of the elderly human diaphragm. Am J Respir Crit Care Med 1997; 155: 1560-1564.
64. Ito K, Mercado N. STOP accelerating lung aging for the treatment of COPD. Exp Gerontol 2014 [In press DOI: 10.1016/j.exger.2014.03.014].
65. Kuroo M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
66. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-1192.
67. Sanchez-Salcedo P, Divo M, Casanova C, et al. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur Respir J 2014; 44: 324-331.
68. Stubbings AK, Moore AJ, Dusmet M, et al. Physiological properties of human diaphragm muscle fibres and the effect of chronic obstructive pulmonary disease. J Physiol 2008; 586: 2637-2650.
69. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax 2006; 61: 568-571.
70. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012; 67: 606-612.
71. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
72. Schöttker B, Saum KU, Jansen EH, et al. Oxidative stress markers and all-cause mortality at older age: a population-based cohort study. J Gerontol A Biol Sci Med Sci 2014 [In press DOI:10.1093/gerona/glu111].
73. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62.
74. Puente-Maestu L, Perez-Parra J, Godoy R, et al. Abnormal transition pore kinetics and cytochrome c release in muscle mitochondria of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009; 40: 746-750.
75. Puente-Maestu L, Perez-Parra J, Godoy R, et al. Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients. Eur Respir J 2009; 33: 1045-1052.
76. Morla M, Busquets X, Pons J, et al. Telomere shortening in smokers with and without COPD. Eur Respir J 2006; 27: 525-528.
77. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366: 662-624.
78. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006; 174: 886-893.
79. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration 2010; 80: 59-70.
80. Tsuji T, Aoshiba K, Nagai A. Cigarette smoke induces senescence in alveolar epithelial cells. Am J Respir Cell Mol Biol 2004; 31: 643-649.
81. Nyunoya T, Monick MM, Klingelhutz A, et al. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol 2006; 35: 681-688.
82. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004; 125: 626-632.
83. Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001; 163: 737-744.
84. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 861-701.
85. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 41-50.
86. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976.
87. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39: 1367-1374.
88. Royce SG, Karagiannis TC. Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions. Curr Opin Allergy Clin Immunol 2014; 14: 44-48.
89. Beerman I, Bhattacharya D, Zandi S, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA 2010; 107: 5465-5470.
90. Shaw AC, Joshi S, Greenwood H, et al. Aging of the innate immune system. Curr Opin Immunol 2010; 22: 507-513.
91. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
92. MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6: 527-531.
93. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011; 184: 904-912.
94. Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol 2008; 59: 169-186.
95. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 566-571.
96. Aviv A. Telomeres and human aging: facts and fibs. Sci Aging Knowledge Environ 2004; 2004: pe43.
97. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92-105.
98. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007; 4: 522-525.
99. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
100. Galgani M, Fabozzi I, Perna F, et al. Imbalance of circulating dendritic cell subsets in chronic obstructive pulmonary disease. Clin Immunol 2010; 137: 102-110.
101. Della BS, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol 2007; 122: 220-228.
102. Shaw AC, Panda A, Joshi SR, et al. Dysregulation of human Toll-like receptor function in aging. Ageing Res Rev 2011; 10: 346-353.
103. Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans. Ageing Res Rev 2011; 10: 336-345.
104. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184: 2518-2527.
105. Givi ME, Redegeld FA, Folkerts G, et al. Dendritic cells in pathogenesis of COPD. Curr Pharm Des 2012; 18: 2329-2335.
106. Lynch HE, Goldberg GL, Chidgey A, et al. Thymic involution and immune reconstitution. Trends Immunol 2009; 30: 366-373.
107. Lambers C, Hacker S, Posch M, et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009; 155: 466-475.
108. Frasca D, Diaz A, Romero M, et al. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011; 10: 330-335.
109. Choudhury G, Rabinovich R, MacNee W. Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35: 101-130.
110. Miller J, Edwards LD, Agustí A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107: 1376-1384.
111. Rosamond W, Flegal K, Furie K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
112. Cheitlin MD. Cardiovascular physiology-changes with aging. Am J Geriatr Cardiol 2003; 12: 9-13.
113. Folkow B, Svanborg A. Physiology of cardiovascular aging. Physiol Rev 1993; 73: 725-764.
114. Priebe HJ. The aged cardiovascular risk patient. Br J Anaesth 2000; 85: 763-778.
115. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993; 88: 1456-1462.
116. Fleg JL, O'Connor FC, Gerstenblith G, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol 1995; 78: 890-900.
117. Ferrari AU, Radaelli A, Centola M. Aging and the cardiovascular system. J Appl Physiol 2003; 95: 2591-2597.
118. Lakatta EG, Gerstenblith G, Angell CS, et al. Prolonged contraction duration in aged myocardium. J Clin Invest 1975; 55: 61-68.
119. Lakatta EG. Cardiovascular aging research: The next horizons. J Am Geriatr Soc 1999; 47: 613-625.
120. Ali Raza J, Movahed A. Use of cardiovascular medications in the elderly. Int J Cardiol 2002; 85: 203-215.
121. Kajstura J, Cheng W, Sarangarajan R, et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol 1996; 271: H1215-H1228.
122. Esler MD, Turner AG, Kaye DM, et al. Aging effects on human sympathetic neuronal function. Am J Physiol 1995; 268: R278- R285.
123. Cigola E, Kajstura J, Li B, et al. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 1997; 231: 363-371.
124. Carneiro-Jú nior MA, Prímola-Gomes TN, Quintão-Jú nior JF, et al. Regional effects of low-intensity endurance training on structural and mechanical properties of rat ventricular myocytes. J Appl Physiol (1985) 2013; 115: 107-115.
125. Eckberg DL, Sleight P, eds. Human Baroreflexes in Health and Disease. Oxford, Clarendon Press, 1992.
126. La Rovere MT, Pinna GD. Beneficial effects of physical activity on baroreflex control in the elderly. Ann Noninvasive Electrocardiol 2014; 19: 303-310.
127. Jones PP, Christou DD, Jordan J, et al. Baroreflex buffering is reduced with age in healthy men. Circulation 2003; 107: 1770-1774.
128. Okada Y, Galbreath MM, Shibata S, et al. Relationship between sympathetic baroreflex sensitivity and arterial stiffness in elderly men and women. Hypertension 2012; 59: 98-104.
129. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982; 66: 874-880.
130. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001; 103: 2072-2077.
131. Klein AL, Leung DY, Murray RD, et al. Effects of age and physiologic variables on right ventricular filling dynamics in normal subjects. Am J Cardiol 1999; 84: 440-448.
132. Ebert TJ, Morgan BJ, Barney JA, et al. Effects of aging on baroreflex regulation of sympathetic activity in humans. Am J Physiol 1992; 263: H798-H803.
133. Huikuri HV, Mäkikallio TH, Airaksinen KE, et al. Power-law relationship of heart rate variability as a predictor of mortality in the elderly. Circulation 1998; 97: 2031-2036.
134. Okazaki K, Iwasaki K, Prasad A, et al. Dose-response relationship of endurance training for autonomic circulatory control in healthy seniors. J Appl Physiol 2005; 99: 1041-1049.
135. Virmani R, Avolio AP, Mergner WJ, et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis: comparison between occidental and Chinese communities. Am J Pathol 1991; 139: 1119-1129.
136. Li Z, Froehlich J, Galis ZS, et al. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 1999; 33: 116-123.
137. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
138. Robert L. Aging of the vascular wall and atherogenesis: role of the elastini-laminin receptor. Atherosclerosis 1996; 123: 169-179.
139. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107: 490-497.
140. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
141. Mattace-Raso FU, van den Meiracker AH, Bos WJ, et al. Arterial stiffness, cardiovagal baroreflex sensitivity and postural blood pressure changes in older adults: The Rotterdam Study. J Hypertens 2007; 25: 1421-1426.
142. Nemes A, Csanády M, Forster T. Does increased aortic stiffness predict reduced coronary flow velocity reserve in patients with suspected coronary artery disease? Acta Physiol Hung 2012; 99: 271-278.
143. Theilade S, Lajer M, Persson F, et al. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 2013; 36: 715-721.
144. Nilsson PM. Hemodynamic aging as the consequence of structural changes associated with early vascular aging (EVA). Aging Dis 2014; 5: 109-113.
145. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: The Framingham Heart Study. Circulation 2009; 119: 243-250.
146. Mitchell GF, Parise H, Benjamin EJ, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: The Framingham Heart Study. Hypertension 2004; 43: 1239-1245.
147. Nilsson PM, Boutouyrie P, Cunha P, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens 2013; 8: 1517-1526.
148. Birru MS, Matthews KA, Thurston RC, et al. African-American ethnicity and cardiovascular risk factors are related to aortic pulse-wave velocity progression. Am J Hypertens 2011; 24: 809-815.
149. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005; 2: 35-41.
150. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
151. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179: 35-40.
152. Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014; 69: 718-723.
153. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-1265.
154. McAllister DA, Maclay JD, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 513-520.
155. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008; 63: 306-311.
156. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 1208-1214.
157. Maclay J, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2014; 143: 798-807.
158. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
159. Minamino T, Miyauchi H, Yoshida T, et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541-1544.
160. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065-1072.
161. Benetos A, Okuda K, Lajemi M, et al. Telomere length as an indicator of biological aging: The gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001; 37: 381-385.
162. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107-114.
163. Papaioannou A, Kennedy CC, Cranney A, et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporosis Int 2009; 20: 507-518.
164. Waugh EJ, Lam MA, Hawker GA, et al. Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature. Osteoporosis Int 2009; 20: 1-21.
165. Syed FA, Ng AC. The pathophysiology of the aging skeleton. Curr Osteoporos Rep 2010; 8: 235-240.
166. Banu J. Causes, consequences, and treatment of osteoporosis in men. Drug Des Devel Ther 2013; 7: 849-860.
167. Gallagher JC. Vitamin D and aging. Endocrinol Metab Clin North Am 2013; 42: 319-332.
168. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286-1293.
169. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136: 1456-1465.
170. Graat-Verboom L, van den Borne BE, Smeenk FW, et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 2011; 26: 561-568.
171. Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest 2011; 139: 648-657.
172. Leech JA, Dulberg C, Kellie S, et al. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141: 68-71.
173. de Luise C, Brimacombe M, Pedersen L, et al. Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study. Eur J Epidemiol 2008; 23: 115-122.
174. Maggi S, Siviero P, Gonnelli S, et al. Osteoporosis risk in patients with chronic obstructive pulmonary disease: The EOLO study. J Clin Densitom 2009; 12: 3 45-52.
175. Coin A, Sergi G, Marin S, et al. Predictors of low bone mineral density in elderly males with chronic obstructive pulmonary disease: The role of body mass index. Aging Male 2010; 13: 142-147.
176. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972-977.
177. DiGirolamo DJ, Kiel DP, Esser KA. Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res 2013; 28: 1509-1518.
178. Yasui A, Nishizawa H, Okuno Y, et al. Foxo1 represses expression of musclin, a skeletal muscle-derived secretory factor. Biochem Biophys Res Commun 2007; 364: 358-365.
179. Moffatt P, Thomas GP. Osteocrin - beyond just another bone protein? Cell Mol Life Sci 2009; 66: 1135-1139.
180. Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther Adv Respir Dis 2011; 5: 217-224.
181. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013; 45: 291-300.
182. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
183. Romme EA, Murchison JT, Edwards LD, et al. CT-measured attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res 2013; 28: 1369-1377.
184. Romme EA, McAllister DA, Murchison JT, et al. Associations between COPD related manifestations: a crosssectional study. Respir Res 2013; 14: 129.
185. Montalcini T, Romeo S, Ferro Y, et al. Osteoporosis in chronic inflammatory disease: The role of malnutrition. Endocrine 2013; 43: 59-64.
186. Incalzi RA, Caradonna P, Ranieri P, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000; 94: 1079-1084.
187. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 1996; 101: 262-269.
188. Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999; 116: 1616-1624.
189. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10-14.
190. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity - A common inflammatory phenotype? Respir Res 2006; 7: 70.
191. Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. J Cell Biochem 2006; 97: 226-232.
192. Almeida M, O'Brien CA. Basic biology of skeletal aging: role of stress response pathways. J Gerontol A Biol Sci Med Sci 2013; 68: 1197-1208.
193. Correa-de-Araujo R, Hadley E. Skeletal muscle function deficit: a new terminology to embrace the evolving concepts of sarcopenia and age-related muscle dysfunction. J Gerontol A Biol Sci Med Sci 2014; 69: 591-594.
194. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerentol A Biol Sci Med Sci 2006; 61: 72-77.
195. Rosenberg I. Summary comments: epidemiological and methodological problems in determining nutritional status of the older persons. Am J Clin Nutr 1989; 50: 1231-1233.
196. Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 2010; 95: 139-159.
197. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.
198. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763.
199. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-896.
200. Delmonico MJ, Harris TB, Lee JS, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 2007; 55: 769-774.
201. Tanko LB, Movsesyan L, Mouritzen U, et al. Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women. Metabolism 2002; 51: 69-74.
202. Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc 2008; 56: 1710-1715.
203. Mitchell WK, Williams J, Atherton P, et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol 2012; 3: 260.
204. Janssen I, Heymsfield SB, Wang ZM, et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol (1985) 2000; 89: 81-88.
205. Laukkanen P, Heikkinen E, Kauppinen M. Muscle strength and mobility as predictors of survival in 75-84-year-old people. Age Ageing 1995; 24: 468-473.
206. Porter MM, Vandervoort AA, Kramer JF. Eccentric peak torque of the plantar and dorsiflexors is maintained in older women. J Gerontol A Biol Sci Med Sci 1997; 52: B125-B131.
207. Frontera WR, Hughes VA, Fielding RA, et al. Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol (1985) 2000; 88: 1321-1326.
208. Yu F, Hedstrom M, Cristea A, et al. Effects of ageing and gender on contractile properties in human skeletal muscle and single fibres. Acta Physiol (Oxf) 2007; 190: 229-241.
209. Macaluso A, De Vito G. Muscle strength, power and adaptations to resistance training in older people. Eur J Appl Physiol 2004; 91: 450-472.
210. Avin KG, Law LA. Age-related differences in muscle fatigue vary by contraction type: a meta-analysis. Phys Ther 2011; 91: 1153-1165.
211. Klitgaard H, Zhou M, Schiaffino S, et al. Ageing alters the myosin heavy chain composition of single fibres from human skeletal muscle. Acta Physiol Scand 1990; 140: 55-62.
212. Gelfi C, Vigano A, Ripamonti M, et al. The human muscle proteome in aging. J Proteome Res 2006; 5: 1344-1353.
213. Marx JO, Kraemer WJ, Nindl BC, et al. Effects of aging on human skeletal muscle myosin heavy-chain mRNA content and protein isoform expression. J Gerontol A Biol Sci Med Sci 2002; 57: B232-B238.
214. Coggan AR, Spina RJ, King DS, et al. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. J Gerontol 1992; 47: B71-B76.
215. Andersen JL. Muscle fibre type adaptation in the elderly human muscle. Scand J Med Sci Sports 2003; 13: 40-47.
216. Kumar V, Selby A, Rankin D, et al. Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men. J Physiol 2009; 587: 211-217.
217. Wilkes EA, Selby AL, Atherton PJ, et al. Blunting of insulin inhibition of proteolysis in legs of older subjects may contribute to age-related sarcopenia. Am J Clin Nutr 2009; 90: 1343-1350.
218. Kadi F, Charifi N, Denis C, et al. Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve 2004; 29: 120-127.
219. Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977; 34: 213-219.
220. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science 1997; 278: 419-424.
221. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820-E826.
222. Ganong WF, ed. Review of Medical Physiology. New York, McGraw Hill, 2005.
223. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-5772.
224. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006; 61: 10-16.
225. Pedersen M, Bruunsgaard H, Weis N, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 2003; 124: 495-502.
226. Giresi PG, Stevenson EJ, Theilhaber J, et al. Identification of a molecular signature of sarcopenia. Physiol Genomics 2005; 21: 253-263.
227. Barreiro E, Coronell C, Lavina B, et al. Aging, sex differences, and oxidative stress in human respiratory and limb muscles. Free Radic Biol Med 2006; 41: 797-809.
228. Engelen MP, Schols AM, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994; 7: 1793-1797.
229. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
230. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1414-1418.
231. Braun SR, Keim NL, Dixon RM, et al. The prevalence and determinants of nutritional changes in chronic obstructive pulmonary disease. Chest 1984; 86: 558-563.
232. Gray-Donald K, Gibbons L, Shapiro SH, et al. Effect of nutritional status on exercise performance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: 1544-1548.
233. Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 629-634.
234. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996; 153: 976-980.
235. Engelen MP, Schols AM, Does JD, et al. Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2000; 71: 733-738.
236. Baarends EM, Schols AM, Mostert R, et al. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2807-2813.
237. Kobayashi A, Yoneda T, Yoshikawa M, et al. The relation of fat-free mass to maximum exercise performance in patients with chronic obstructive pulmonary disease. Lung 2000; 178: 119-127.
238. Schols AM, Mostert R, Soeters PB, et al. Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax 1991; 46: 695-699.
239. van den Borst B, Koster A, Yu B, et al. Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking? Thorax 2011; 66: 961-969.
240. Rutten EP, Calverley PM, Casaburi R, et al. Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab 2013; 63: 239-247.
241. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res 2007; 8: 25.
242. Maltais F, Sullivan MJ, Leblanc P, et al. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J 1999; 13: 850-854.
243. Maltais F, Leblanc P, Whittom F, et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000; 55: 848-853.
244. Simard C, Maltais F, Leblanc P, et al. Mitochondrial and capillarity changes in vastus lateralis muscle of COPD patients: Electron Microscopy Study. Med Sci Sports Exerc 1996; 28: S95.
245. Jobin J, Maltais F, Doyon JF, et al. Chronic obstructive pulmonary disease: capillarity and fiber characteristics of skeletal muscle. J Cardiopulm Rehabil 1998; 18: 432-437.
246. Morrison WL, Gibson J, Scrimegeour C, et al. Muscle wasting in emphysema. Clin Sci 1988; 75: 415-420.
247. Aguilaniu B, Goldstein-Shapses S, Pajon A, et al. Muscle protein degradation in severely malnourished patients with chronic obstructive pulmonary disease subject to short-term total parenteral nutrition. JPEN J Parenter Enteral Nutr 1992; 16: 248-254.
248. Wilson DO, Donahoe M, Rogers RM, et al. Metabolic rate and weight loss in chronic obstructive lung disease. J Parenter Enteral Nutr 1990; 14: 7-11.
249. Decramer M, De Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 1958-1964.
250. Preedy VR, Smith DM, Sugden PH. The effects of 6 hours of hypoxia on protein synthesis in rat tissues in vivo and in vitro. Biochem J 1985; 228: 179-185.
251. Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest 2007; 37: 897-904.
252. Rabinovich RA, Figueras M, Ardite E, et al. Increased tumour necrosis factor-a plasma levels during moderateintensity exercise in COPD patients. Eur Respir J 2003; 21: 789-794.
253. Rabinovich RA, Ardite E, Troosters T, et al. Reduced muscle redox capacity after endurance training in COPD patients. Am J Respir Crit Care Med 2001; 164: 1114-1118.
254. Rabinovich RA, Bastos R, Ardite E, et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J 2007; 29: 643-650.
255. Theriault ME, Pare ME, Maltais F, et al. Satellite cells senescence in limb muscle of severe patients with COPD. PloS One 2012; 7: e39124.
256. Ito K, Colley T, Mercado N. Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease. Int J Chron Obstruct Pulmon Dis 2012; 7: 641-652.
257. Malhotra D, Thimmulappa RK, Mercado N, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest 2011; 121: 4289-4302.
258. Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009; 106: 250-255.
259. Yao H, Chung S, Hwang JW, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012; 122: 2032-2045.
260. Bulterijs S. Metformin as a geroprotector. Rejuvenation Res 2011; 14: 469-482.
261. de Matos Cavalcante AG, de Bruin PF, de Bruin VM, et al. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo controlled study. J Pineal Res 2012; 53: 238-244.
262. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-d with theophylline reverses corticosteroid insensitivity COPD. Am J Respir Crit Care Med 2010; 182: 897-904.
263. Babar P, Adamson C, Walker GA, et al. P13-kinase inhibition induces dauer formation, thermotolerance and longevity in C. elegans. Neurobiol Aging 1999; 20: 513-519.
264. Bjedov I, Partridge L. A longer and healthier life with TOR down-regulation: genetics and drugs. Biochem Soc Trans 2011; 39: 460-465.
265. Beltrami AP, Cesselli D, Beltrami CA. Stem cell senescence and regenerative paradigms. Clin Pharmacol Ther 2012; 91: 21-29.
266. Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013; 143: 1590-1598.
267. Melk A, Tegtbur U, Hilfiker-Kleiner D, et al. Improvement of biological age by physical activity. Int J Cardiol 2014 [In press DOI: 10.1016/j.ijcard.2014.07.236].
268. Heikkila HM, Krachler B, Rauramaa R, et al. Diet, insulin secretion and insulin sensitivity - the Dose-Responses to Exercise Training (DR's EXTRA) Study (ISRCTN45977199). Br J Nutr 2014; 18: 1-12.
269. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.